Lercanidipina DOC Generici

Lercanidipina DOC Generici is a generic pharmaceutical product specifically used to treat hypertension (high blood pressure). It contains the active ingredient lercanidipine hydrochloride, which belongs to a class of drugs known as calcium channel blockers. The product is marketed by DOC Generici, a major player in the Italian off-patent medicine market.

DOC Generici was founded in 1996 in Italy by a consortium including Chiesi Farmaceutici, Zambon, and Apotex to focus on the growing demand for affordable generic alternatives. Over the years, the company underwent several ownership changes, eventually becoming one of Italy's leading generic drug providers. Manufacturing typically takes place in Italy or through European partners specialized in pharmaceutical production.

In 2022, the brand was acquired by Intermediate Capital Group (ICG) and Merieux Equity Partners. As of 2026, it remains part of a investment portfolio managed by ICG, reflecting its status as a critical asset in the European healthcare and generic medicine sector with a primary focus on the Italian domestic market.